Literature DB >> 31669645

The roles and regulation of TBX3 in development and disease.

Saif F Khan1, Victoria Damerell1, Rehana Omar1, Michelle Du Toit1, Mohsin Khan1, Hapiloe Mabaruti Maranyane1, Mihlali Mlaza1, Jenna Bleloch1, Claire Bellis1, Bianca D B Sahm2, Jade Peres1, K N ArulJothi1, Sharon Prince3.   

Abstract

TBX3, a member of the ancient and evolutionary conserved T-box transcription factor family, is a critical developmental regulator of several structures including the heart, mammary glands, limbs and lungs. Indeed, mutations in the human TBX3 lead to ulnar mammary syndrome which is characterized by several clinical malformations including hypoplasia of the mammary and apocrine glands, defects of the upper limb, areola, dental structures, heart and genitalia. In contrast, TBX3 has no known function in adult tissues but is frequently overexpressed in a wide range of epithelial and mesenchymal derived cancers. This overexpression greatly impacts several hallmarks of cancer including bypass of senescence, apoptosis and anoikis, promotion of proliferation, tumour formation, angiogenesis, invasion and metastatic capabilities as well as cancer stem cell expansion. The debilitating consequences of having too little or too much TBX3 suggest that its expression levels need to be tightly regulated. While we have a reasonable understanding of the mutations that result in low levels of functional TBX3 during development, very little is known about the factors responsible for the overexpression of TBX3 in cancer. Furthermore, given the plethora of oncogenic processes that TBX3 impacts, it must be regulating several target genes but to date only a few have been identified and characterised. Interestingly, while there is compelling evidence to support oncogenic roles for TBX3, a few studies have indicated that it may also have tumour suppressor functions in certain contexts. Together, the diverse functional elasticity of TBX3 in development and cancer is thought to involve, in part, the protein partners that it interacts with and this area of research has recently received some attention. This review provides an insight into the significance of TBX3 in development and cancer and identifies research gaps that need to be explored to shed more light on this transcription factor.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Co-factors; Heart development; Limb development; Lung development; Mammary gland development; Obesity; Rheumatoid arthritis; Signalling; Stem cells; T-box factors; TBX3; Target genes; Transcription factor; Ulnar mammary syndrome

Mesh:

Substances:

Year:  2019        PMID: 31669645      PMCID: PMC7108957          DOI: 10.1016/j.gene.2019.144223

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  190 in total

1.  The Rb network.

Authors:  James DeGregori
Journal:  J Cell Sci       Date:  2004-07-15       Impact factor: 5.285

2.  Structure of the DNA-bound T-box domain of human TBX3, a transcription factor responsible for ulnar-mammary syndrome.

Authors:  Miquel Coll; Jonathan G Seidman; Christoph W Müller
Journal:  Structure       Date:  2002-03       Impact factor: 5.006

3.  Tbx3 and Nr5α2 play important roles in pig pluripotent stem cells.

Authors:  Jianyu Wang; Qi Gu; Jie Hao; Yundan Jia; Binghua Xue; Honghong Jin; Jing Ma; Renyue Wei; Tang Hai; Qingran Kong; Gerelchimeg Bou; Ping Xia; Qi Zhou; Liu Wang; Zhonghua Liu
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

4.  RDH10 is essential for synthesis of embryonic retinoic acid and is required for limb, craniofacial, and organ development.

Authors:  Lisa L Sandell; Brian W Sanderson; Gennadiy Moiseyev; Teri Johnson; Arcady Mushegian; Kendra Young; Jean-Philippe Rey; Jian-xing Ma; Karen Staehling-Hampton; Paul A Trainor
Journal:  Genes Dev       Date:  2007-05-01       Impact factor: 11.361

5.  Tbx3 represses E-cadherin expression and enhances melanoma invasiveness.

Authors:  Mercedes Rodriguez; Ewa Aladowicz; Luisa Lanfrancone; Colin R Goding
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

6.  Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.

Authors:  Claire-Angélique Renard; Charlotte Labalette; Carolina Armengol; Delphine Cougot; Yu Wei; Stefano Cairo; Pascal Pineau; Christine Neuveut; Aurélien de Reyniès; Anne Dejean; Christine Perret; Marie-Annick Buendia
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

8.  Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo.

Authors:  Arnaud André Mailleux; Bradley Spencer-Dene; Christian Dillon; Delphine Ndiaye; Catherine Savona-Baron; Nobuyuki Itoh; Shigeaki Kato; Clive Dickson; Jean Paul Thiery; Saverio Bellusci
Journal:  Development       Date:  2002-01       Impact factor: 6.868

9.  Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer.

Authors:  Nicole M A White-Al Habeeb; Linh T Ho; Ekaterina Olkhov-Mitsel; Ken Kron; Vaijayanti Pethe; Melanie Lehman; Lidija Jovanovic; Neil Fleshner; Theodorus van der Kwast; Colleen C Nelson; Bharati Bapat
Journal:  Oncotarget       Date:  2014-09-15

Review 10.  The T-box family.

Authors:  Val Wilson; Frank L Conlon
Journal:  Genome Biol       Date:  2002-05-31       Impact factor: 13.583

View more
  11 in total

1.  Heritable genomic diversity in breast cancer driver genes and associations with risk in a Chilean population.

Authors:  Sebastian Morales-Pison; Patricio Gonzalez-Hormazabal; Julio C Tapia; Alexis Salas-Burgos; Sandra Ampuero; Fernando Gómez; Enrique Waugh; José Miguel Reyes; Lilian Jara
Journal:  Biol Res       Date:  2022-05-31       Impact factor: 7.634

2.  Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma.

Authors:  Beilei Liu; Xiaona Fang; Dora Lai-Wan Kwong; Yu Zhang; Krista Verhoeft; Lanqi Gong; Baifeng Zhang; Jie Chen; Qianqian Yu; Jie Luo; Ying Tang; Tuxiong Huang; Fei Ling; Li Fu; Qian Yan; Xin-Yuan Guan
Journal:  J Exp Clin Cancer Res       Date:  2022-05-25

3.  TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.

Authors:  Binyong Liang; Yi Zhou; Manning Qian; Meng Xu; Jingxiao Wang; Yi Zhang; Xinhua Song; Haichuan Wang; Shumei Lin; Chuanli Ren; Satdarshan P Monga; Bruce Wang; Matthias Evert; Yifa Chen; Xiaoping Chen; Zhiyong Huang; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2021-02-10       Impact factor: 30.083

4.  Establishment of the TBX-code reveals aberrantly activated T-box gene TBX3 in Hodgkin lymphoma.

Authors:  Stefan Nagel; Corinna Meyer
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

5.  Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.

Authors:  Charles M Rudin; Alvaro Quintanal-Villalonga; Hirokazu Taniguchi; Yingqian A Zhan; Maysun M Hasan; Shweta S Chavan; Fanli Meng; Fathema Uddin; Viola Allaj; Parvathy Manoj; Nisargbhai S Shah; Joseph M Chan; Metamia Ciampricotti; Andrew Chow; Michael Offin; Jordana Ray-Kirton; Jacklynn D Egger; Umesh K Bhanot; Irina Linkov; Marina Asher; Michael H Roehrl; Katia Ventura; Juan Qiu; Elisa de Stanchina; Jason C Chang; Natasha Rekhtman; Brian Houck-Loomis; Richard P Koche; Helena A Yu; Triparna Sen
Journal:  J Hematol Oncol       Date:  2021-10-16       Impact factor: 17.388

6.  The WNT7A/WNT7B/GPR124/RECK signaling module plays an essential role in mammalian limb development.

Authors:  Yanshu Wang; Arjun Venkatesh; Jiajia Xu; Mingxin Xu; John Williams; Philip M Smallwood; Aaron James; Jeremy Nathans
Journal:  Development       Date:  2022-05-12       Impact factor: 6.862

7.  Single-cell transcriptomic landscape of the sheep rumen provides insights into physiological programming development and adaptation of digestive strategies.

Authors:  Yuan Yuan; Da-Ming Sun; Tao Qin; Sheng-Yong Mao; Wei-Yun Zhu; Yu-Yang Yin; Jie Huang; Rasmus Heller; Zhi-Peng Li; Jun-Hua Liu; Qiang Qiu
Journal:  Zool Res       Date:  2022-07-18

8.  TBX3 and EFNA4 Variant in a Family with Ulnar-Mammary Syndrome and Sagittal Craniosynostosis.

Authors:  Moon Ley Tung; Bharatendu Chandra; Jaclyn Kotlarek; Marcelo Melo; Elizabeth Phillippi; Cristina M Justice; Anthony Musolf; Simeon A Boyadijev; Paul A Romitti; Benjamin Darbro; Hatem El-Shanti
Journal:  Genes (Basel)       Date:  2022-09-14       Impact factor: 4.141

9.  The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma.

Authors:  Danica Sims; Hapiloe Mabaruti Maranyane; Victoria Damerell; Dhirendra Govender; Ashwin W Isaacs; Jade Peres; Sharon Prince
Journal:  Cancers (Basel)       Date:  2020-02-21       Impact factor: 6.639

10.  Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.

Authors:  Peitao Zhang; Haixia Guan; Shukai Yuan; Huili Cheng; Jian Zheng; Zhenlei Zhang; Yifan Liu; Yang Yu; Zhaowei Meng; Xiangqian Zheng; Li Zhao
Journal:  Nat Commun       Date:  2022-03-24       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.